{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:28:59Z","timestamp":1790814539667,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2003,4,29]],"date-time":"2003-04-29T00:00:00Z","timestamp":1051574400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2003,5]]},"DOI":"10.1038\/sj.bjc.6600916","type":"journal-article","created":{"date-parts":[[2003,5,30]],"date-time":"2003-05-30T15:29:09Z","timestamp":1054308549000},"page":"1339-1345","source":"Crossref","is-referenced-by-count":77,"title":["Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate"],"prefix":"10.1038","volume":"88","author":[{"given":"S","family":"Amat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Bougnoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Penault-Llorca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"F\u00e9tissof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Cur\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Kwiatkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J-L","family":"Achard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Body","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Dauplat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Chollet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2003,4,29]]},"reference":[{"key":"BF6600916_CR1","first-page":"3","volume":"25","author":"HD Bear","year":"1998","unstructured":"Bear HD (1998) Indications for neoadjuvant chemotherapy for breast cancer. Semin Oncol 25(2 Suppl 3): 3\u201312","journal-title":"Semin Oncol"},{"key":"BF6600916_CR2","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1200\/JCO.1998.16.1.93","volume":"16","author":"G Bonadonna","year":"1998","unstructured":"Bonadonna G, Valagussa P, Brambilla C, Ferrari L, Moliterni A, Terenziani M, Zambetti M (1998) Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 16: 93\u2013100","journal-title":"J Clin Oncol"},{"key":"BF6600916_CR3","first-page":"3","volume":"25","author":"DR Brenin","year":"1998","unstructured":"Brenin DR, Morrow M (1998) Breast-conserving surgery in the neoadjuvant setting. Semin Oncol 25(2 Suppl 3): 3\u201318","journal-title":"Semin Oncol"},{"key":"BF6600916_CR4","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1002\/1097-0142(19940815)74:4<1283::AID-CNCR2820740417>3.0.CO;2-S","volume":"74","author":"G Calais","year":"1994","unstructured":"Calais G, Berger C, Descamps P, Chapet S, Reynaud-Bougnoux A, Body G, Bougnoux P, Lansac J, Le Floch O (1994) Conservative treatment feasibility with induction chemotherapy, surgery, and radiotherapy for patients with breast carcinoma larger than 3 cm. Cancer 74: 1283\u20131288","journal-title":"Cancer"},{"key":"BF6600916_CR5","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1200\/JCO.1999.17.8.2341","volume":"17","author":"S Chan","year":"1999","unstructured":"Chan S, Friedrichs K, Noel D, Pinter T, Van Belle S, Vorobiof D, Duarte R, Gil Gil M, Bodrogi I, Murray E, Yelle L, von Minckwitz G, Korec S, Simmonds P, Buzzi F, Gonzalez Mancha R, Richardson G, Walpole E, Ronzoni M, Murawsky M, Alakl M, Riva A (1999) Prospective randomized trial of docetaxel vs doxorubicin in patients with metastatic breast cancer. The 303 study group. J Clin Oncol 17: 2341\u20132354","journal-title":"J Clin Oncol"},{"key":"BF6600916_CR6","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1200\/JCO.1995.13.2.314","volume":"13","author":"B Chevallier","year":"1995","unstructured":"Chevallier B, Fumoleau P, Kerbrat P, Dieras V, Roche H, Krakowski I, Azli N, Bayssas M, Lentz MA, Van Glabbeke M (1995) Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 13: 314\u2013322","journal-title":"J Clin Oncol"},{"key":"BF6600916_CR7","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1097\/00000421-199306000-00006","volume":"16","author":"B Chevallier","year":"1993","unstructured":"Chevallier B, Roche H, Olivier JP, Chollet P, Hurteloup P (1993) Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol 16: 223\u2013228","journal-title":"Am J Clin Oncol"},{"key":"BF6600916_CR8","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/S0959-8049(97)00038-5","volume":"33","author":"P Chollet","year":"1997","unstructured":"Chollet P, Charrier S, Brain E, Cure H, van Praagh I, Feillel V, de Latour M, Dauplat J, Misset JL, Ferriere JP (1997) Clinical and pathological response to primary chemotherapy in operable breast cancer. Eur J Cancer 33: 862\u2013866","journal-title":"Eur J Cancer"},{"key":"BF6600916_CR9","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1200\/JCO.1995.13.10.2643","volume":"13","author":"JE Cortes","year":"1995","unstructured":"Cortes JE, Pazdur R (1995) Docetaxel. J Clin Oncol 13: 2643\u20132655","journal-title":"J Clin Oncol"},{"key":"BF6600916_CR10","first-page":"24","volume":"26","author":"SD Costa","year":"1999","unstructured":"Costa SD, von Minckwitz G, Raab G, Blohmer JU, Dresel V, Eidtmann H, Hilfrich J, Jackisch C, Merkle E, Gademann G, Kaufmann M (1999) The role of docetaxel (Taxotere) in neoadjuvant chemotherapy of breast cancer. Semin Oncol 26(3 Suppl 9): 24\u201331","journal-title":"Semin Oncol"},{"key":"BF6600916_CR11","first-page":"31","volume":"84","author":"H Cure","year":"1997","unstructured":"Cure H, Charrier S, Ferriere JP, Van Praagh I, Assier I, Feillel V, De Latour M, Bay JO, Achard JL, Dauplat J, Chollet P (1997) First-line chemotherapy in operable breast neoplasms: results of 3 protocols. Bull Cancer 84: 31\u201334","journal-title":"Bull Cancer"},{"key":"BF6600916_CR12","first-page":"315","volume":"64","author":"L Est\u00e9vez","year":"2000","unstructured":"Est\u00e9vez L, Cuevas JM, Ant\u00f3n A (2000) A phase II study of weekly docetaxel (TXT) as primary chemotherapy (PC) in stage II and III breast cancer: preliminary results. Breast Cancer Res Treat 64: 315","journal-title":"Breast Cancer Res Treat"},{"key":"BF6600916_CR13","first-page":"2578","volume":"46","author":"LD Feldman","year":"1986","unstructured":"Feldman LD, Hortobagyi GN, Buzdar AU, Ames FC, Blumenschein GR (1986) Pathologic assessment of response to induction chemotherapy in breast cancer. Cancer Res 46: 2578\u20132581","journal-title":"Cancer Res"},{"key":"BF6600916_CR14","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/00000421-199804000-00003","volume":"21","author":"JP Ferriere","year":"1998","unstructured":"Ferriere JP, Assier I, Cure H, Charrier S, Kwiatkowski F, Achard JL, Dauplat J, Chollet P (1998) Primary chemotherapy in breast cancer: correlation between tumor response and patient outcome. Am J Clin Oncol 21: 117\u2013120","journal-title":"Am J Clin Oncol"},{"key":"BF6600916_CR15","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1200\/JCO.1995.13.3.537","volume":"13","author":"B Fisher","year":"1995","unstructured":"Fisher B, Mamounas EP (1995) Preoperative chemotherapy: a model for studying the biology and therapy of primary breast cancer cancer. J Clin Oncol 13: 537\u2013540","journal-title":"J Clin Oncol"},{"key":"BF6600916_CR16","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1200\/JCO.1997.15.7.2483","volume":"15","author":"B Fisher","year":"1997","unstructured":"Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, Cruz Jr AB, Fisher ER, Wickerham DL, Wolmark N, DeCillis A, Hoehn JL, Lees AW, Dimitrov NV (1997) Effect of preoperative chemotherapy on local\u2013regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15: 2483\u20132493","journal-title":"J Clin Oncol"},{"key":"BF6600916_CR17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/BF00666069","volume":"33","author":"P Fumoleau","year":"1995","unstructured":"Fumoleau P, Chevallier B, Kerbrat P (1995) Current status of Taxotere (docetaxel) as a new treatment in breast cancer. Breast Cancer Res Treat 33: 39\u201346","journal-title":"Breast Cancer Res Treat"},{"key":"BF6600916_CR18","first-page":"15","volume":"11","author":"WJ Gradishar","year":"1997","unstructured":"Gradishar WJ (1997) Docetaxel as neoadjuvant chemotherapy in patients with stage III breast cancer. Phase II study: preliminary results. Oncology 11(Suppl 8): 15\u201318","journal-title":"Oncology"},{"key":"BF6600916_CR19","first-page":"25","volume":"25","author":"WJ Gradishar","year":"1998","unstructured":"Gradishar WJ (1998) Primary chemotherapy regimens and schedules. Semin Oncol 25(2 Suppl 3): 25\u201330","journal-title":"Semin Oncol"},{"key":"BF6600916_CR20","first-page":"26","volume":"26","author":"WJ Gradishar","year":"1999","unstructured":"Gradishar WJ (1999) Recently initiated studies: neoadjuvant treatments in the next century. Semin Oncol 26(1 Suppl 3): 26\u201329","journal-title":"Semin Oncol"},{"key":"BF6600916_CR21","first-page":"310","volume":"46","author":"WJ Gradishar","year":"1997","unstructured":"Gradishar WJ, Loh KL, Erban J (1997) Preliminary results from a phase II study of (Taxotere\u00ae) docetaxel as primary chemotherapy followed by doxorubicin and cyclophosphamide in stage III breast cancer. Breast Cancer Res Treat 46: 310","journal-title":"Breast Cancer Res Treat"},{"key":"BF6600916_CR22","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/1097-0142(19900701)66:1<119::AID-CNCR2820660122>3.0.CO;2-3","volume":"66","author":"C Jacquillat","year":"1990","unstructured":"Jacquillat C, Weil M, Baillet F, Borel C, Auclerc G, de Maublanc MA, Housset M, Forget G, Thill L, Soubrane C (1990) Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer. Cancer 66(1): 119\u2013129","journal-title":"Cancer"},{"key":"BF6600916_CR23","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1023\/A:1012534724488","volume":"70","author":"T Kato","year":"2001","unstructured":"Kato T, Kameoka S, Kimura T, Soga N, Abe Y, Nishikawa T, Kobayashi M (2001) Angiogenesis as a predictor of long-term survival for 377 Japanese patients with breast cancer. Breast Cancer Res Treat 70(1): 65\u201374","journal-title":"Breast Cancer Res Treat"},{"key":"BF6600916_CR24","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1200\/JCO.1999.17.2.460","volume":"17","author":"HM Kuerer","year":"1999","unstructured":"Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, Buchholz TA, Ross MI, McNeese MD, Buzdar AU, Hortobagyi GN, Singletary SE (1999) Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17: 460\u2013469","journal-title":"J Clin Oncol"},{"key":"BF6600916_CR25","first-page":"31","volume":"25","author":"EP Mamounas","year":"1998","unstructured":"Mamounas EP (1998) Overview of National Surgical Adjuvant Breast Project neoadjuvant chemotherapy studies. Semin Oncol 25(2 Suppl 3): 31\u201335","journal-title":"Semin Oncol"},{"key":"BF6600916_CR26","first-page":"S26","volume":"33","author":"M Marty","year":"1997","unstructured":"Marty M, Extra JM, Cottu PH, Espie M (1997) Prospects with docetaxel in the treatment of patients with breast cancer. Eur J Cancer 33(Suppl 7): S26\u2013S29","journal-title":"Eur J Cancer"},{"key":"BF6600916_CR27","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1093\/oxfordjournals.annonc.a057953","volume":"2","author":"L Mauriac","year":"1991","unstructured":"Mauriac L, Durand M, Avril A, Dilhuydy JM (1991) Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Ann Oncol 2: 347\u2013354","journal-title":"Ann Oncol"},{"key":"BF6600916_CR28","first-page":"520","volume":"8","author":"S Menard","year":"2002","unstructured":"Menard S, Balsari A, Casalini P, Tagliabue E, Campiglio M, Bufalino R, Cascinelli N (2002) HER-2-positive breast carcinomas as a particular subset with peculiar clinical behaviors. Clin Cancer Res 8(2): 520\u2013525","journal-title":"Clin Cancer Res"},{"key":"BF6600916_CR29","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","volume":"47","author":"AB Miller","year":"1981","unstructured":"Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207\u2013214","journal-title":"Cancer"},{"key":"BF6600916_CR30","first-page":"23","volume":"12","author":"J O'Leary","year":"1998","unstructured":"O'Leary J, Volm M, Wasserheit C, Muggia F (1998) Taxanes in adjuvant and neoadjuvant therapies for breast cancer. Oncology 12(1 Suppl 1): 23\u201327","journal-title":"Oncology"},{"key":"BF6600916_CR31","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1200\/JCO.1995.13.3.547","volume":"13","author":"TJ Powles","year":"1995","unstructured":"Powles TJ, Hickish TF, Makris A, Ashley SE, O'Brien ME, Tidy VA, Casey S, Nash AG, Sacks N, Cosgrove D, Macvicar D, Fernando I, Ford HT (1995) Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 13: 547\u2013552","journal-title":"J Clin Oncol"},{"key":"BF6600916_CR32","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1200\/JCO.1995.13.12.2879","volume":"13","author":"PM Ravdin","year":"1995","unstructured":"Ravdin PM, Burris III HA, Cook G, Eisenberg P, Kane M, Bierman WA, Mortimer J, Genevois E, Bellet RE (1995) Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13: 2879\u20132885","journal-title":"J Clin Oncol"},{"key":"BF6600916_CR33","first-page":"297","volume":"180","author":"DM Sataloff","year":"1995","unstructured":"Sataloff DM, Mason BA, Prestipino AJ, Seinige UL, Lieber CP, Baloch Z (1995) Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 180: 297\u2013306","journal-title":"J Am Coll Surg"},{"key":"BF6600916_CR34","first-page":"48","volume":"6","author":"SM Scholl","year":"1995","unstructured":"Scholl SM, Asselain B, Beuzeboc P (1995) Neoadjuvant vs adjuvant chemotherapy in premenopausal patients with tumours considered too large for conserving surgery: an update. Anti-Cancer Drugs 6: 48","journal-title":"Anti-Cancer Drugs"},{"key":"BF6600916_CR35","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1016\/0277-5379(91)90442-G","volume":"27","author":"SM Scholl","year":"1991","unstructured":"Scholl SM, Asselain B, Palangie T, Dorval T, Jouve M, Garcia Giralt E, Vilcoq J, Durand JC, Pouillart P (1991) Neoadjuvant chemotherapy in operable breast cancer. Eur J Cancer 27: 1668\u20131671","journal-title":"Eur J Cancer"},{"key":"BF6600916_CR36","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/0959-8049(94)90537-1","volume":"30A","author":"SM Scholl","year":"1994","unstructured":"Scholl SM, Fourquet A, Asselain B, Pierga JY, Vilcoq JR, Durand JC, Dorval T, Palangie T, Jouve M, Beuzeboc P, Garciogiralt E, Salmon RJ, Delarochefordiere A, Campana F, Pouillart P (1994) Neoadjuvant vs adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer 30A: 645\u2013652","journal-title":"Eur J Cancer"},{"key":"BF6600916_CR37","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1200\/JCO.2002.20.6.1456","volume":"20","author":"IC Smith","year":"2002","unstructured":"Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S, Gilbert FJ, Ah-See AK, Eremin O, Walker LG, Sarkar TK, Eggleton SP, Ogston KN (2002) Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 20(6): 1456\u20131466","journal-title":"J Clin Oncol"},{"key":"BF6600916_CR38","first-page":"3889","volume":"47","author":"SM Swain","year":"1987","unstructured":"Swain SM, Sorace RA, Bagley CS, Danforth Jr DN, Bader J, Wesley MN, Steinberg SM, Lippman ME (1987) Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. Cancer Res 47: 3889\u20133894","journal-title":"Cancer Res"},{"key":"BF6600916_CR39","first-page":"13","volume":"24","author":"V Valero","year":"1997","unstructured":"Valero V (1997) Docetaxel as single-agent therapy in metastatic breast cancer: clinical efficacy. Semin Oncol 24(Suppl 13): 13\u201318","journal-title":"Semin Oncol"},{"key":"BF6600916_CR40","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1200\/JCO.1995.13.12.2886","volume":"13","author":"V Valero","year":"1995","unstructured":"Valero V, Holmes FA, Walters RS, Theriault RL, Esparza L, Fraschini G, Fonseca GA, Bellet RE, Buzdar AU, Hortobagyi GN (1995) Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 13: 2886\u20132894","journal-title":"J Clin Oncol"},{"key":"BF6600916_CR41","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1200\/JCO.1999.17.7.1999","volume":"17","author":"G von Minckwitz","year":"1999","unstructured":"von Minckwitz G, Costa SD, Eiermann W, Blohmer JU, Tulusan AH, Jackisch C, Kaufmann M (1999) Maximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and docetaxel. J Clin Oncol 17: 1999\u20132005","journal-title":"J Clin Oncol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6600916.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6600916","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6600916.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:49:23Z","timestamp":1684414163000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6600916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,4,29]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2003,5]]}},"alternative-id":["BF6600916"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6600916","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,4,29]]}}}